GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2008

BioFocus Inks Target Discovery Agreement in Oncology with Janssen Worth about $15.5M

  • BioFocus DPI stands to make 10.5 million, or about $15.45 million, through a deal inked with Janssen Pharmaceutica in oncology. The two-year target discovery collaboration will use an adenoviral platform from parent company, Galapagos, to identify novel drug targets.

    BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation.  Target discovery in in vitro assays may provide novel drug targets for cancer areas with an unmet medical need, according to the firms. 

    BioFocus DPI will receive an upfront payment of 2.9 million. Janssen will also pay additional research, acceptance, license, and development fees of up to 7.6 million should certain predetermined criteria be achieved.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?